Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
3.7
4.7
Journals
Biomedicines
Special Issues
Pathogenesis and Treatment of Preeclampsia
share announcement

Pathogenesis and Treatment of Preeclampsia

A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Molecular and Translational Medicine".

Deadline for manuscript submissions: 31 August 2024 | Viewed by 816

Special Issue Editors

Dr. Patrizia Vergani

E-Mail Website
Guest Editor
Department of Obstetrics and Gynecology, University of Milano-Bicocca, 20900 Monza, Italy
Interests: maternal–fetal medicine; high risk pregnancy; prenatal diagnosis; placental angiogenic markers
Dr. Valentina Giardini

E-Mail Website
Guest Editor
Department of Obstetrics and Gynecology, IRCCS San Gerardo dei Tintori Foundation, University of Milano-Bicocca, 20900 Monza, Italy
Interests: angiogenic markers (PlGF and sFlt-1); preeclampsia; maternal–fetal medicine

Special Issue Information

Dear Colleagues,

Preeclampsia is a pregnancy-specific hypertensive disorder with multisystem involvement. It is one of the “great obstetrical syndromes” with multiple etiologic factors that converge to an angiogenic imbalance, such as endothelial dysfunction.

Preeclampsia complicates 5–8% of pregnancies worldwide and is one of the main causes of maternal and perinatal morbidity and mortality. Despite the increase in knowledge of its pathogenesis, there is no specific cure for this disease, other than delivery. Therefore, there is an urgent need for therapeutic strategies to prolong pregnancy in the case of early-onset forms and to prevent/reduce maternal–fetal–neonatal complications.

This Special Issue aims to collate research that explores all potential therapies for the prevention and treatment of preeclampsia, in the light of new etiopathogenetic evidence.

Dr. Patrizia Vergani
Dr. Valentina Giardini
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • preeclampsia
  • hypertensive disorders of pregnancy
  • placental dysfunction
  • endothelial dysfunction
  • therapy
  • angiogenic imbalance

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

13 pages, 9683 KiB  
Article
Expression of IMP3 and LIN28A RNA-Binding Proteins in Placentas of Patients with Pre-Eclampsia with and without Severe Features
by Maja Barbaric, Katarina Vukojevic, Anita Kolobaric, Martina Orlovic Vlaho, Tanja Kresic and Violeta Soljic
Biomedicines 2024, 12(4), 879; https://0-doi-org.brum.beds.ac.uk/10.3390/biomedicines12040879 - 16 Apr 2024
Viewed by 471
Abstract
Background: this study aimed to determine the expression of RNA-binding oncofetal proteins IMP3 and LIN28A in extravillous (EVT) and villous trophoblast (VT) cells of placentas from pre-eclamptic (PE) pregnancies to better understand the pathogenesis of PE. Methods: placental tissue of 10 patients with [...] Read more.
Background: this study aimed to determine the expression of RNA-binding oncofetal proteins IMP3 and LIN28A in extravillous (EVT) and villous trophoblast (VT) cells of placentas from pre-eclamptic (PE) pregnancies to better understand the pathogenesis of PE. Methods: placental tissue of 10 patients with PE with severe features, 10 patients with PE without severe features and 20 age-matched healthy pregnancy controls were analyzed by immunohistochemistry, double immunofluorescence and qPCR. Results: We found a decreased percentage of IMP3-positive EVT cells in PE with and without severe features compared to that of the healthy control (p < 0.001). IMP3 expression was significantly low in VT of PE placentas compared to that of the healthy control (p = 0.002). There was no significant difference in LIN28A expression between groups of PE and the control group. Additionally, we noticed the trend toward downregulation of IMP3 mRNA and LIN28A mRNA in severe PE compared to that of healthy controls. Conclusions: We demonstrated that IMP3 expression is decreased in EVT and VT cells of placentas from pregnancies complicated with both PE with and without severe features. However, additional functional investigations are needed to clarify the role of IMP3 as a potential therapeutic target in the management of PE. Full article
(This article belongs to the Special Issue Pathogenesis and Treatment of Preeclampsia)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop